Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Current Health—purchased by Best Buy for $400 million in 2021—is set to become an independent company again, with co-founder Christopher McGhee taking over. The electronics retailer appears to be backing away from remote patient monitoring services, shifting its healthcare division's focus to consumer products that improve the lives of seniors.
The U.S. is one of 23 countries that consider workforce AI training and education only a medium priority. Indeed, our homeland has a less detailed plan than 13 other nations.
The legal case brought by all 50 states, Washington D.C., and multiple U.S. territories against Purdue Pharma and the Sackler family has come to an end, with settlement funds set to be used for addiction recovery.
A class-action lawsuit claims CVS Health sent text messages to customers and patients, inciting fear over a PBM regulation up for vote in Louisiana. Plaintiffs allege the incident violates state data privacy and political communication laws.
A “sophisticated cybercrime group” is being blamed for an attack on the network of the private insurer, which may have exposed social security numbers and protected health information. The incident is still being investigated.
A former employee at Nuance Communications, a Microsoft subsidiary, stands accused of taking patient data from Geisinger Health system shortly after their termination.
The failing health system allegedly hired intelligence firms that put a tracking device on a car, accessed a personal smartphone to find lurid information on an executive and attempted to frame a politician for bribery.
The U.S. is far from alone in the world in its wranglings across public and private sectors to adopt propitious healthcare AI innovations quickly yet safely.
MeMD offers on-demand telehealth services to more than 5 million patients. Fabric said the buyout will be a smooth transition with no impact on patient care.
One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.